Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fourth Dose of Pfizer mRNA COVID-19 Vaccine in LTCF Residents
NCT04978038Phase 4Unknown
- Start
- Aug 2022
- Primary completion
- Nov 2022
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of tozinameran in coronavirus disease 2019 (COVID-19) (2 arms). Primary endpoint: Detection of neutralizing antibodies at 28 days. Status: unknown.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04978038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04978038.